<DOC>
	<DOCNO>NCT02656485</DOCNO>
	<brief_summary>This single center , randomize , double-blind , placebo-controlled study subject acne vulgaris .</brief_summary>
	<brief_title>A Double Blind , Placebo-Controlled , Randomized Study Subjects With Acne Vulgaris</brief_title>
	<detailed_description>After screen visit one-week washout ( applicable ) , three sequential ascend dos study drug apply twice-daily ( BID ) 14 day three group subject . Each group subject randomize receive plan dos B244 placebo BID</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Male female subject ≥18 ≤45 year age 2 . In good general health determine thorough medical history physical examination , electrocardiogram ( ECG ) , vital sign , clinical laboratory evaluation . Results clinical laboratory test must without clinically significant abnormality , include hematology , clinical chemistry urinalysis . 3 . Clinical diagnosis facial acne vulgaris define : ≥105 inflammatory lesion ≥10 noninflammatory lesion IGA ≥2 4 . Willing refrain use treatment , investigational product , include antibiotic , acne present face . Topical acne treatment significant measurable systemic absorption ( e.g. , benzoyl peroxide , salicylic acid ) allow treatment acne back , shoulder chest . 5 . Ability comprehend comply procedure 6 . Agree commit participate current protocol 7 . Provide write informed consent prior study procedure perform ( subject able understand inform consent form document subject require read ) 1 . Female subject pregnant lactate try conceive 2 . Female subject positive urine βhuman chorionic gonadotropin ( βhCG ) test screen positive βhCG urine predose 3 . Any clinically relevant abnormality identify screen history , physical laboratory examination , medical condition circumstance make volunteer unsuitable participation study 4 . Any skin condition may interfere evaluation safety acne vulgaris ( e.g. , rosacea ; seborrheic dermatitis ; perioral dermatitis ; corticosteroidinduced acne folliculitis ) 5 . Use tan booth excessive sun exposure , opinion investigator 6 . Active cystic acne acne congoblata , acne fulminans , secondary acne 7 . Two active nodular lesion 8 . Treatment overthecounter topical medication treatment acne vulgaris include benzoyl peroxide , topical antiinflammatory medication , corticosteroid , αhydroxy/glycolic acid face within 2 week prior baseline 9 . Treatment systemic corticosteroid ( include intranasal inhaled corticosteroid ) within 4 week prior baseline 10 . Treatment systemic antibiotic systemic antiacne drug systemic antiinflammatory drug within 4 week prior baseline 11 . Prescription topical retinoid use face within 4 week baseline ( e.g. , tretinoin , tazarotene , adapalene ) 12 . Treatment hormonal therapy dose change hormonal therapy within 12 week prior baseline . Dose frequency use hormonal therapy start 12 week prior baseline must remain unchanged throughout study . Hormonal therapy include , limited , estrogenic progestational agent birth control pill . 13 . Use androgen receptor blocker ( spironolactone flutamide ) 14 . Oral retinoid use ( e.g. , isotretinoin ) within 12 month prior baseline vitamin A supplement great 10,000 units/day within 6 month baseline 15 . Facial procedure ( chemical laser peel , microdermabrasion , etc . ) within 8 week first dose study 16 . A positive urine drug screen drug abuse , include alcohol positive urine cotinine ( ≥300 ng/mL cotinine ) screen visit entry clinic ( Note : urine cotinine require screening visit ) 17 . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior begin screen period ( include investigational formulation market product , inhaled topical drug ) 18 . Hypersensitivity B244 components 19 . Blood collection great 500 mL within 56 day prior screen 20 . Seropositive human immunodeficiency virus ( HIV ) screen 21 . Positive Hepatitis B virus surface antigen ( HBsAg ) positive Hepatitis C virus antibody ( HCV Ab ) screen 22 . Any condition and/or situation cause Investigator deem subject unsuitable study ( e.g. , due expect study medication noncompliance , inability medically tolerate study procedure , subject 's unwillingness comply studyrelated procedure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>